Our Facilities & Pipeline

Duopharma Biotech has three R&D and manufacturing facilities across the Klang Valley in Malaysia – in Klang, Bangi and Glenmarie.


The facility in Klang is a GMP-certified factory pioneering advanced pharmaceutical technologies, manufacturing Halal pharmaceutical products comprising a wide array of tablets, capsules, syrups, oral antibiotic creams, solutions for haemodialysis and sterile irrigation, sterile powders, injectables, small volume injectables, dental cartridges and eye drop preparations – for the local and export markets. In addition, R&D and stability studies of different formulations are also conducted here.


The facility in Bangi, originally established in 1976, manufactures a wide range of Ethical and over-the-counter products, mainly in Oral Solid Dose (OSD), liquid and cream forms. It is equipped with a state-of-the-art Intermediate Bulk Container (IBC) manufacturing format, capable of manufacturing 1-ton batches for tablets, capsules and mini-tablets in capsules.

Glenmarie, Shah Alam

The facility in Glenmarie, Shah Alam is the company’s in-house pharmaceutical R&D facility, offering scientific and technical knowledge in the development of high quality, safe and efficacious pharmaceutical products. Staffed by over 30 multi-disciplinary scientists including pharmacists, microbiologists, analytical chemists and various other specialists in the life sciences, the state-of-the-art R&D centre has ISO/IEC 17025 accreditation. It is equipped with the latest laboratory technology including six high-performance liquid chromatography (HPLC) machines, two ultra-performance liquid chromatography (UPLC) machines, five dissolution testers and lab scale equipment for formulation trials. 

One milestone achievement by the team is the development of OMESEC mini-tablet capsules in 2001, which was recognised as the ‘Best Innovative Product’ at the ‘Industry Excellence Awards’ organised by the Ministry of International Trade and Industry Malaysia in 2004.

Our Pipeline

Duopharma Biotech’s pipeline reflects our focus on high-value niche areas such as digital health, regenerative medicine, neurodegenerative diseases and biotherapeutics.

We aim to lead the way in the industry and are exploring less-prominent fields such as therapies for rare and orphan diseases, 4D bioprinting or digital diagnostics.

We see the pharmaceutical industry moving towards patient-centric value creation, where digital transformation supports individual healthcare providers as well as the healthcare ecosystem holistically, improving how the system works, developing ease of access to services, and enhancing patient and clinician experience.  Medical prognostic, diagnostic and therapeutic technologies such as biotechnology, gene and cell therapy and precision medicine will gain wider application and prominence, in turn transforming the medical sector.